Table 2.
Prevalence of Transmitted Drug Resistance Mutations in Recently Infected Patients and in Patients With an Unknown Duration of Infection, Diagnosed During 2008–2010
| Mutation | Recently Infected Patients (n = 534), % | Patients With an Unknown Duration of Infection (n = 3606), % | P Value |
|---|---|---|---|
| TDR prevalence | |||
| TDR any class | 10.1 | 8.2 | NS |
| TDR NRTI | 4.7 | 4.4 | NS |
| TDR NNRTI | 3.8 | 2.9 | NS |
| TDR PI | 2.4 | 2.0 | NS |
| NRTI mutations | |||
| T215reva | 3 | 2.47 | NS |
| M41L | 1.57 | 1.47 | NS |
| D67N | 0.20 | 0.68 | NS |
| K219Q | 0.20 | 0.52 | NS |
| L210W | 0.79 | 0.35 | NS |
| M184V | 0 | 0.27 | NS |
| NNRTI mutations | |||
| E138Ab | 3.15 | 3.62 | NS |
| K103N | 3.35 | 1.49 | .0055 |
| G190A | 0 | 0.52 | NS |
| Y181C | 0.20 | 0.46 | NS |
| Y181V | 0 | 0.03 | NS |
| K101E | 0 | 0.27 | NS |
| K101P | 0.20 | 0.08 | NS |
| K103S | 0.39 | 0.19 | NS |
| P225H | 0 | 0.16 | NS |
| Y188L | 0 | 0.16 | NS |
| PI mutations | |||
| L90M | 0.38 | 0.58 | NS |
| M46I | 0.38 | 0.26 | NS |
| M46L | 0.38 | 0.24 | NS |
| V82A | 0.19 | 0.18 | NS |
Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NS, not significant (P value >.05); PI, protease inhibitor; TDR, transmitted drug resistance.
a T215rev represent revertant mutations (S/D/C/E/I/V) that can occur at position 215.
b E138A is a polymorphic mutation. This mutation is for this reason not included in the World Health Organization list for surveillance of TDR mutations. As this list is used to determine the prevalence of TDR, this mutation is not included in the prevalence of TDR for NNRTIs.